Clinical trial · no report yet · Phase 3
TROPION-Lung14
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06350097 ↗
- Recruiting
- AstraZeneca
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 7 | |
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Osimertinib; Datopotamab Deruxtecan
- Arms
- Arm 1: Osimertinib in combination with Datopotamab Deruxtecan · Experimental
- Arm 2: Osimertinib monotherapy · Active comparator
- Enrollment
- 582 (estimated)
- Primary outcomes
- To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants.
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Apr 29, 2024
- Primary completion
- Mar 21, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06350097 · updated Aug 26, 2026
Publications
linked from the registry- Lu S, Pulla MP, Mascarenhas E, Tanizaki J, Kim HR, Liu Y, Feng S, Zhang B, Toms L, Yang JC, Goldberg SB. TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer. Ther Adv Med Oncol. 2026 May 20;18:17588359261430561. doi: 10.1177/17588359261430561. eCollection 2026. PubMed 42182601